AR056186A1 - Compuesto de imidazo[1,2-a]piridinilo, su uso para la fabricacion de un medicamento y formulacion farmaceutica que lo comprende - Google Patents
Compuesto de imidazo[1,2-a]piridinilo, su uso para la fabricacion de un medicamento y formulacion farmaceutica que lo comprendeInfo
- Publication number
- AR056186A1 AR056186A1 ARP060100668A ARP060100668A AR056186A1 AR 056186 A1 AR056186 A1 AR 056186A1 AR P060100668 A ARP060100668 A AR P060100668A AR P060100668 A ARP060100668 A AR P060100668A AR 056186 A1 AR056186 A1 AR 056186A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- nhr6
- cyanoalkyl
- pyridinyl
- 4nr2r3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Uso del compuesto descripto para la fabricacion de un medicamento para inhibir VEGF-R2, bloquear la angiogénesis, el tratamiento de neoplasmas y la supresion de angiogénesis tumoral. Formulacion farmacéutica que lo comprende en combinacion con un vehículo, diluyente o solvente, farmacéuticamente aceptables. Reivindicacion 1: Un compuesto de imidazo[1,2-a]piridinilo caracterizado porque tiene la formula (1), donde R1 es (a) 2-piridonilo opcionalmente substituido con -(CH2)1-4NR2R3; o (b) fenilo, tienilo, tiazolilo, imidazolilo, pirazolilo, triazolilo, oxazolilo, piridinilo, N-oxo-piridinilo, o pirimidinilo, todos ellos son opcionalmente substituido con -(CH2)0-4NR2R3, alquilo C1-6 opcionalmente substituido con amino, pirrolidinilo, o morfolinilo, o 1-2 substituyentes independientemente seleccionado de un grupo consistente de alcoxi C1-4, halo, (alquil C1-6)sulfonilo, nitro, -sulfonil(CH2)0-4NR2R3, y -carbonil(CH2)0-4NR2R3; R2 es hidrogeno o alquilo C1-6 opcionalmente substituido con hidroxi; R3 es hidrogeno o alquilo C1-6 opcionalmente substituido con hidroxi, trifluorometilo, o pirrolidinilo; o R2, R3, y el nitrogeno al cual son enlazados, forman piperidinilo, piperazinilo opcionalmente substituido con alquilo C1-6, o morfolinilo; R4 es tiazolilo, piridinilo, o fenilo opcionalmente substituido con 1-3 substituyentes seleccionados de un grupo consistente de halo, amino, metilo, trifluorometilo, y nitro; R5 es C(O)NHR6, OC(O)NHR6, NHC(O)CH2R6, NHC(O)NHR6 o C(S)NHR6; n es 0-4 por OC(O)NHR6, NHC(O)CH2R6, NHC(O)NHR6 y n es 1-4 por C(O)NHR6 y C(S)NHR6; y R6 es (a) tetrahidrobenzotiazolilo insubstituido; o (b) fenilo, piridinilo, pirimidinilo, pirazolilo, tiazolilo, isotiazolilo, tiadiazolilo, isoxazolilo, todos ellos son opcionalmente substituidos con 1-3 substituyentes independientemente seleccionados de un grupo consistente de alquilo C1-6 opcionalmente substituido con hidroxi, dimetilamino, pirrolidinilo, piperidinilo, o morfolinilo, alquenilo C2- 6 opcionalmente substituido con dimetilaminocarbonilo, alcoxi C1-6, trifluorometilo, difluorometoxi, trifluorometoxi, dimetilaminoetoxi, fenoxi, tolilo, halo, metilsulfonilo, dimetilamino, dietilamino, ciano, cicloalquilo C3-6 opcionalmente substituido con hidroxi, metoxi, metoxietoxi, o metilo, 3,4-dimetilisoxazol-5-il-aminosulfonilo, tetrahidropiranilo, tetrahidropiranilaminocarbonilo, alquilcarbonilo C1-6, morfolinilcarbonilo, y piperazinilcarbonilo; o sales del mismo farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65598105P | 2005-02-24 | 2005-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056186A1 true AR056186A1 (es) | 2007-09-26 |
Family
ID=36587138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100668A AR056186A1 (es) | 2005-02-24 | 2006-02-23 | Compuesto de imidazo[1,2-a]piridinilo, su uso para la fabricacion de un medicamento y formulacion farmaceutica que lo comprende |
Country Status (34)
Country | Link |
---|---|
US (1) | US7666879B2 (es) |
EP (1) | EP1904494B1 (es) |
JP (1) | JP5055136B2 (es) |
KR (1) | KR100904938B1 (es) |
CN (1) | CN101128461B (es) |
AR (1) | AR056186A1 (es) |
AT (1) | ATE490254T1 (es) |
AU (1) | AU2006216710B2 (es) |
BR (1) | BRPI0609047A2 (es) |
CA (1) | CA2599124C (es) |
CR (1) | CR9331A (es) |
CY (1) | CY1111154T1 (es) |
DE (1) | DE602006018615D1 (es) |
DK (1) | DK1904494T3 (es) |
DO (1) | DOP2006000051A (es) |
EA (1) | EA011691B1 (es) |
ES (1) | ES2354716T3 (es) |
HK (1) | HK1118284A1 (es) |
HR (1) | HRP20100677T1 (es) |
IL (1) | IL184717A (es) |
MA (1) | MA29433B1 (es) |
MX (1) | MX2007010326A (es) |
NO (1) | NO20074666L (es) |
NZ (2) | NZ560402A (es) |
PE (1) | PE20061098A1 (es) |
PL (1) | PL1904494T3 (es) |
PT (1) | PT1904494E (es) |
RS (1) | RS51590B (es) |
SI (1) | SI1904494T1 (es) |
TN (1) | TNSN07323A1 (es) |
TW (1) | TW200640924A (es) |
UA (1) | UA91535C2 (es) |
WO (1) | WO2006091671A1 (es) |
ZA (1) | ZA200707136B (es) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895745B2 (en) * | 2006-12-22 | 2014-11-25 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as FGFR inhibitors |
JP5442449B2 (ja) * | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
CN101669030B (zh) | 2007-03-08 | 2016-01-13 | 小利兰·斯坦福大学托管委员会 | 线粒体醛脱氢酶2调节剂和其使用方法 |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
CA2703037A1 (en) * | 2007-10-17 | 2009-04-23 | Novartis Ag | Organic compounds |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
JP2012502048A (ja) | 2008-09-08 | 2012-01-26 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法 |
US8389522B2 (en) | 2008-10-28 | 2013-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modulators of aldehyde dehydrogenase and methods of use thereof |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
TW201124391A (en) | 2009-10-20 | 2011-07-16 | Lundbeck & Co As H | 2-substituted-ethynylthiazole derivatives and uses of same |
GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
AR090566A1 (es) * | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
US9738636B2 (en) | 2012-09-28 | 2017-08-22 | Vanderbilt University | Fused heterocyclic compounds as selective BMP inhibitors |
KR101735975B1 (ko) * | 2012-11-29 | 2017-05-15 | 에프. 호프만-라 로슈 아게 | 이미다조피리딘 유도체 |
JP6410790B2 (ja) | 2013-03-14 | 2018-10-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | ミトコンドリアアルデヒドデヒドロゲナーゼ−2調節因子およびその使用方法 |
AU2014365823B2 (en) | 2013-12-16 | 2019-05-02 | Abs Development 1, Inc. | P2X3 and/or P2X2/3 compounds and methods |
CN103772308B (zh) * | 2013-12-31 | 2015-11-18 | 北京颖泰嘉和生物科技股份有限公司 | 5-氨基-3-(1-乙基-1-甲基丙基)异噁唑中间体的制备方法和异噁草胺的制备方法 |
US9988371B2 (en) | 2014-06-03 | 2018-06-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Benzimidazole analogues and related methods |
KR102485100B1 (ko) | 2014-07-17 | 2023-01-04 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 치환된 우레아 유도체 및 이의 약제학적 용도 |
CN104163790B (zh) * | 2014-08-19 | 2016-02-10 | 贵州威顿晶磷电子材料股份有限公司 | 一种2-氨基-4-甲基-5溴吡啶的制备工艺 |
US10829484B2 (en) | 2015-07-28 | 2020-11-10 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP2018526452A (ja) * | 2015-09-03 | 2018-09-13 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ | Dyrk1aの小分子抑制剤およびその使用 |
WO2017161045A1 (en) * | 2016-03-16 | 2017-09-21 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
WO2019178383A1 (en) | 2018-03-14 | 2019-09-19 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
US10239885B1 (en) | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
MX2021007925A (es) | 2018-12-31 | 2021-10-26 | Biomea Fusion Llc | Inhibidores irreversibles de la interaccion menina-mll. |
EP3906029A4 (en) | 2018-12-31 | 2022-09-21 | Biomea Fusion, LLC | INHIBITORS OF MENIN-MLL INTERACTION |
MX2021009251A (es) * | 2019-01-30 | 2021-09-21 | Avista Pharma Solutions Inc | Proceso de sintesis y nuevos compuestos intermedios. |
EP3917932A4 (en) | 2019-01-30 | 2022-09-28 | Avista Pharma Solutions, Inc. | CHEMICAL COMPOUNDS |
US20220098204A1 (en) * | 2019-02-18 | 2022-03-31 | Shenzhen Targetrx, Inc. | Substituted fused aromatic ring derivative, composition and use thereof |
CN114466847A (zh) * | 2019-06-25 | 2022-05-10 | 西诺普塞疗法公司 | 用于治疗癌症的化合物 |
CN112778294A (zh) * | 2021-01-07 | 2021-05-11 | 苏州安睿药业有限公司 | 5-氨基异噁唑衍生物及其在制备多激酶抑制剂中的应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
EP1017682A4 (en) | 1997-09-26 | 2000-11-08 | Merck & Co Inc | NEW ANGIOGENESIS INHIBITORS |
ES2253233T3 (es) | 1999-07-09 | 2006-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Procedimiento para sintesis de compuestos de urea heteroaril sustituidos. |
US6492529B1 (en) * | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
US6916814B2 (en) | 2001-07-11 | 2005-07-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediated diseases |
JP2003313126A (ja) * | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
CA2483084A1 (en) * | 2002-05-02 | 2003-11-13 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2004052315A2 (en) * | 2002-12-11 | 2004-06-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
AU2003298942A1 (en) * | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
CA2535416A1 (en) | 2003-08-15 | 2005-02-24 | Banyu Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
-
2006
- 2006-02-22 DO DO2006000051A patent/DOP2006000051A/es unknown
- 2006-02-23 EP EP06735794A patent/EP1904494B1/en active Active
- 2006-02-23 ES ES06735794T patent/ES2354716T3/es active Active
- 2006-02-23 RS RS20110042A patent/RS51590B/en unknown
- 2006-02-23 TW TW095106022A patent/TW200640924A/zh unknown
- 2006-02-23 AR ARP060100668A patent/AR056186A1/es not_active Application Discontinuation
- 2006-02-23 DK DK06735794.7T patent/DK1904494T3/da active
- 2006-02-23 PL PL06735794T patent/PL1904494T3/pl unknown
- 2006-02-23 DE DE602006018615T patent/DE602006018615D1/de active Active
- 2006-02-23 EA EA200701802A patent/EA011691B1/ru not_active IP Right Cessation
- 2006-02-23 CN CN2006800060044A patent/CN101128461B/zh not_active Expired - Fee Related
- 2006-02-23 AU AU2006216710A patent/AU2006216710B2/en not_active Ceased
- 2006-02-23 US US11/816,416 patent/US7666879B2/en not_active Expired - Fee Related
- 2006-02-23 PT PT06735794T patent/PT1904494E/pt unknown
- 2006-02-23 MX MX2007010326A patent/MX2007010326A/es active IP Right Grant
- 2006-02-23 NZ NZ560402A patent/NZ560402A/en not_active IP Right Cessation
- 2006-02-23 BR BRPI0609047-8A patent/BRPI0609047A2/pt not_active IP Right Cessation
- 2006-02-23 JP JP2007557126A patent/JP5055136B2/ja not_active Expired - Fee Related
- 2006-02-23 PE PE2006000219A patent/PE20061098A1/es not_active Application Discontinuation
- 2006-02-23 KR KR1020077019338A patent/KR100904938B1/ko not_active IP Right Cessation
- 2006-02-23 UA UAA200709559A patent/UA91535C2/ru unknown
- 2006-02-23 AT AT06735794T patent/ATE490254T1/de active
- 2006-02-23 WO PCT/US2006/006283 patent/WO2006091671A1/en active Application Filing
- 2006-02-23 CA CA2599124A patent/CA2599124C/en not_active Expired - Fee Related
- 2006-02-23 SI SI200630871T patent/SI1904494T1/sl unknown
- 2006-02-23 NZ NZ584753A patent/NZ584753A/en not_active IP Right Cessation
-
2007
- 2007-07-19 IL IL184717A patent/IL184717A/en not_active IP Right Cessation
- 2007-08-22 CR CR9331A patent/CR9331A/es not_active Application Discontinuation
- 2007-08-23 ZA ZA200707136A patent/ZA200707136B/xx unknown
- 2007-08-23 TN TNP2007000323A patent/TNSN07323A1/en unknown
- 2007-09-13 NO NO20074666A patent/NO20074666L/no not_active Application Discontinuation
- 2007-09-24 MA MA30233A patent/MA29433B1/fr unknown
-
2008
- 2008-08-25 HK HK08109446.3A patent/HK1118284A1/xx not_active IP Right Cessation
-
2010
- 2010-12-07 HR HR20100677T patent/HRP20100677T1/hr unknown
-
2011
- 2011-02-03 CY CY20111100115T patent/CY1111154T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056186A1 (es) | Compuesto de imidazo[1,2-a]piridinilo, su uso para la fabricacion de un medicamento y formulacion farmaceutica que lo comprende | |
IL278297B2 (en) | Transmutable heterocyclic PTPN11 inhibitors | |
AR053364A1 (es) | Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis | |
RU2018105549A (ru) | Производные бензодиазепина как ингибиторы rsv | |
MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
JP2015503625A5 (es) | ||
AR035548A1 (es) | Compuestos organicos | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
RU2502730C2 (ru) | Сульфонамидные соединения и их применение | |
RU2009125578A (ru) | Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний | |
AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
JP2012505879A5 (es) | ||
RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
AR043959A1 (es) | Derivados de indolona-acetamida, procesos para prepararlos, composiciones farmaceuticas que los contienen y su uso como productos farmaceuticos | |
ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
UY29739A1 (es) | Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones | |
RU2015117647A (ru) | Новые производные пиразола | |
GEP20115240B (en) | Indole derivatives, process for their preparation and pharmaceutical compositions containing them | |
SV2007002357A (es) | Derivado de quinolina, su uso, preparacion y medicamento que lo contiene ref. p-sv-79232/ug | |
JP2017525734A5 (es) | ||
RU2017108909A (ru) | Производные изохинолинона, полезные для лечения рака | |
BRPI0707203C1 (pt) | compostos derivados de indoloquinoxalina úteis para o tratamento de infecções virais, método para preparar os compostos, e, composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |